个性化文献订阅>文章检索

文章名     作者     期刊名     摘要     卷     期         如果没有找到您所需要的文献，请点击 ——此处申请     共35条记录   Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia [作者：Yan, XJ; Dozmorov, I; Li, WT; Yancopoulos, S; Sison, C; Centola, M; Jain, P; Allen, SL; Kolitz, JE; Rai, KR; Chiorazzi, N; Sherry, B,期刊：Blood, 页码：5201-5210 , 文章类型： Article，,卷期：2011年118-19] Individual cytokines and groups of cytokines that might represent networks in chronic lymphocytic leukemia (CLL) were analyzed and their prognostic values determined. Serum levels of 23 cytokines were measured in 84 pati... Multiple HLA class I and II associations in classical Hodgkin lymphoma and EBV status defined subgroups [作者：Huang, X; Kushekhar, K; Nolte, I; Kooistra, W; Visser, L; Bouwman, I; Kouprie, N; Veenstra, R; van Imhoff, G; Olver, B; Houlston, RS; Poppema, S; Diepstra, A; Hepkema, B; van den Berg, A,期刊：Blood, 页码：5211-5217 , 文章类型： Article，,卷期：2011年118-19] The pathogenesis of classical Hodgkin lymphoma (cHL) involves environmental and genetic factors. To explore the role of the human leukocyte antigen (HLA) genes, we performed a case-control genotyping study in 338 Dutch c... Proof of principle for transfusion of in vitro-generated red blood cells [作者：Giarratana, MC; Rouard, H; Dumont, A; Kiger, L; Safeukui, I; Le Pennec, PY; Francois, S; Trugnan, G; Peyrard, T; Marie, T; Jolly, S; Hebert, N; Mazurier, C; Mario, N; Harmand, L; Lapillonne, H; Devaux, JY; Douay, L,期刊：Blood, 页码：5071-5079 , 文章类型： Article，,卷期：2011年118-19] In vitro RBC production from stem cells could represent an alternative to classic transfusion products. Until now the clinical feasibility of this concept has not been demonstrated. We addressed the question of the capac... Lack of clarity in the definition of treatment-related mortality: pediatric acute leukemia and adult acute promyelocytic leukemia as examples [作者：Ethier, MC; Blanco, E; Lehrnbecher, T; Sung, L,期刊：Blood, 页码：5080-5083 , 文章类型： Article，,卷期：2011年118-19] Treatment-related mortality (TRM) is important in acute lymphoblastic leukemia and acute myeloid leukemia (AML); however, little is known about how TRM is defined across trials. Two major problems are related to what con... Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? [作者：Ustun, C; Miller, JS; Munn, DH; Weisdorf, DJ; Blazar, BR,期刊：Blood, 页码：5084-5095 , 文章类型： Review，,卷期：2011年118-19] The microenviroment of acute myelogenous leukemia (AML) is suppressive for immune effector cells. Regulatory T cells (Tregs) have been recognized as a contributor factor and may be recruited and exploited by leukemic cel... Blood consult: high Sokal risk chronic myeloid leukemia and suboptimal response [作者：Roy, L; Tomowiak, C; Guilhot, F,期刊：Blood, 页码：5096-5098 , 文章类型： Editorial Material，,卷期：2011年118-19] Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study [作者：Ben Abdelali, R; Asnafi, V; Leguay, T; Boissel, N; Buzyn, A; Chevallier, P; Thomas, X; Lepretre, S; Huguet, F; Vey, N; Escoffre-Barbe, M; Tavernier, E; Reman, O; Fegueux, N; Turlure, P; Rousselot, P; Cahn, JY; Lheritier, V; Chalandon, Y; Bene, MC; Macintyre, E; Dombret, H; Ifrah, N,期刊：Blood, 页码：5099-5107 , 文章类型： Article，,卷期：2011年118-19] Despite recent progress in the understanding of acute lymphoblastic leukemia (T-ALL) oncogenesis, few markers are sufficiently frequent in large subgroups to allow their use in therapeutic stratification. Low ERG and BAA... Major histocompatibility complex class II expression deficiency caused by a RFXANK founder mutation: a survey of 35 patients [作者：Ouederni, M; Vincent, QB; Frange, P; Touzot, F; Scerra, S; Bejaoui, M; Bousfiha, A; Levy, Y; Lisowska-Grospierre, B; Canioni, D; Bruneau, J; Debre, M; Blanche, S; Abel, L; Casanova, JL; Fischer, A; Picard, C,期刊：Blood, 页码：5108-5118 , 文章类型： Article，,卷期：2011年118-19] Inherited deficiency of major histocompatibility complex (MHC) class II molecules impairs antigen presentation to CD4(+) T cells and results in combined immunodeficiency (CID). Autosomal-recessive mutations in the RFXANK... Aphase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma [作者：Fehniger, TA; Larson, S; Trinkaus, K; Siegel, MJ; Cashen, AF; Blum, KA; Fenske, TS; Hurd, DD; Goy, A; Schneider, SE; Keppel, CR; Wagner-Johnston, ND; Carson, KR; Bartlett, NL,期刊：Blood, 页码：5119-5125 , 文章类型： Article，,卷期：2011年118-19] Relapsed or refractory (rel/ref) classical Hodgkin lymphoma (cHL) remains a clinical challenge, with limited effective treatment options available after stem cell transplantation. In a multicenter phase 2 study, the effi... Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study [作者：Wierda, WG; Padmanabhan, S; Chan, GW; Gupta, IV; Lisby, S; Osterborg, A,期刊：Blood, 页码：5126-5129 , 文章类型： Article，,卷期：2011年118-19] Ofatumumab, the human CD20 monoclonal antibody that binds a distinct epitope from rituximab, has demonstrated clinical benefit as monotherapy for patients with chronic lymphocytic leukemia refractory to fludarabine and a... CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues [作者：Sisirak, V; Vey, N; Vanbervliet, B; Duhen, T; Puisieux, I; Homey, B; Bowman, EP; Trinchieri, G; Dubois, B; Kaiserlian, D; Lira, SA; Puisieux, A; Blay, JY; Caux, C; Bendriss-Vermare, N,期刊：Blood, 页码：5130-5140 , 文章类型： Article，,卷期：2011年118-19] Absent in peripheral tissues during homeostasis, human plasmacytoid dendritic cells (pDCs) are described in inflamed skin or mucosa. Here, we report that, unlike blood pDCs, a subset of tonsil pDCs express functional CCR... CD147 (Basigin/Emmprin) identifies FoxP3(+)CD45RO(+)CTLA4(+)-activated human regulatory T cells [作者：Solstad, T; Bains, SJ; Landskron, J; Aandahl, EM; Thiede, B; Tasken, K; Torgersen, KM,期刊：Blood, 页码：5141-5151 , 文章类型： Article，,卷期：2011年118-19] Human CD4(+)FoxP3(+)T cells are functionally and phenotypically heterogeneous providing plasticity to immune activation and regulation. To better understand the functional dynamics within this subset, we first used a com... Overactivation of plasmacytoid dendritic cells inhibits antiviral T-cell responses: a model for HIV immunopathogenesis [作者：Boasso, A; Royle, CM; Doumazos, S; Aquino, VN; Biasin, M; Piacentini, L; Tavano, B; Fuchs, D; Mazzotta, F; Lo Caputo, S; Shearer, GM; Clerici, M; Graham, DR,期刊：Blood, 页码：5152-5162 , 文章类型： Article，,卷期：2011年118-19] Adelicate balance between immunostimulatory and immunosuppressive signals mediated by dendritic cells (DCs) and other antigen-presenting cells (APCs) regulates the strength and efficacy of antiviral T-cell responses. HIV... Wnt4 regulates thymic cellularity through the expansion of thymic epithelial cells and early thymic progenitors [作者：Heinonen, KM; Vanegas, JR; Brochu, S; Shan, JD; Vainio, SJ; Perreault, C,期刊：Blood, 页码：5163-5173 , 文章类型： Article，,卷期：2011年118-19] Thymus atrophy is the most common immunopathology in humans, and its occurrence is hastened by several factors that coalesce in patients receiving chemotherapy and most of all in recipients of hematopoietic cell transpla... Human T cells expressing two additional receptors (TETARs) specific for HIV-1 recognize both epitopes [作者：Hofmann, C; Hofflin, S; Huckelhoven, A; Bergmann, S; Harrer, E; Schuler, G; Dorrie, J; Schaft, N; Harrer, T,期刊：Blood, 页码：5174-5177 , 文章类型： Article，,卷期：2011年118-19] Adoptive TCR transfer against rapidly mutating targets, such as HIV-1 or cancer, must counteract corresponding immune escape. Hence, we generated T cells expressing two additional receptors (TETARs) specific for HIV-1 by... CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101 [作者：Jak, M; van Bochove, GGW; Reits, EA; Kallemeijn, WW; Tromp, JM; Umana, P; Klein, C; van Lier, RAW; van Oers, MHJ; Eldering, E,期刊：Blood, 页码：5178-5188 , 文章类型： Article，,卷期：2011年118-19] Sensitivity of chronic lymphocytic leukemia (CLL) cells to anti-CD20 mAbs is low and, therefore, the efficacy of monotherapy with current anti-CD20 mAbs is limited. At present, it is not known whether sensitivity of CLL ...